SMAIS-ULM
risdiplam
In patients who received risdiplam for 24 months, the mean change from baseline (95% CI) in the caregiver-reported SMAIS-ULM total score was 2.7 (1.7–3.7) at month 24 (Table Change in caregiver- and patient-reported SMAIS upper limb total score from baseline in patients receiving risdiplam for up to 24 months and those who previously received placebo up to study month 12. In patients who initially received placebo, the mean change from baseline in the caregiver-reported SMAIS-ULM total score was 1.6 (0.4–2.8) after 12 months of risdiplam treatment (Table 